Kim Innes becomes chair of BGMA

Replaces Michael Cann who will continue as vice-chair for another year

Kim Innes has replaced Actavis director Michael Cann as chair of the British Generic Manufacturers Association (BGMA).

Innes, a commercial director responsible for Teva UK’s generics business, will remain in the position for the next two years.

Cann will continue for a further year as vice-chair of the association, which is the generic industry’s trade body representing more than 90% of the UK supply market.

Innes has worked in the generics industry since 1991, said: ‘Over the coming two years, we will continue to focus on our three core objectives of increasing patient access to medicines, maintaining market efficiency and providing economic sustainability for the industry.’

You may also like

Regulatory

BGMA reacts to Sir John Bell's findings on the UK life sciences sector

Reaction from the British Generic Manufacturers Association (BGMA) to Sir John Bell outlining his findings into how the life sciences sector can work with the UK government to provide an even greater economic and societal contribution
Regulatory

Further reaction to the EU referendum result

Comments from British Generic Manufacturers Association and the British Biosimilars Association, and APBI
Regulatory

NHS England publishes authoritative information on biosimilar medicines

Document provides key clinical and non-clinical stakeholders with accessible information on how to support the appropriate use of all biological medicines
Pharmaceutical

DoH and BGMA announce joint generics initiative

Will look at IP, evergreening, patent law, exclusivity and regulation, among other issues
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Subscribe now